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LEGAL IMPLICATIONS OF CLINICAL INVESTIGATION
by HOWARD N. MORSE*
I. INTRODUCTION
There is an increasing concern among the members of the medical
profession with legal rights, obligations, and limitations affecting clinical
investigation. This is understandable in light of the virtual explosion of
clinical investigation within medical science.
Clinical investigation is the systematic collection, evaluation, and re-
porting, by or under the supervision of physicians, of data about other
human beings for the purpose of advancing scientific medical knowl-
edge. It thus includes neither investigation relating to animals (even
though such investigation may also advance scientific medical knowl-
edge), investigation of human beings for purposes unrelated to medical
science, nor the trial of unproven procedures in the treatment of pa-
tients unless this is also a part of a systematic program of clinical investi-
gation. Nevertheless, clinical investigation need not occur within the
physician-patient relationship which arises when a person seeks and a
physician undertakes to furnish medical diagnosis or treatment. For
example, a person who volunteers as a subject of clinical investigation
does not have a physician-patient relationship with a physician who
does not undertake to furnish him any medical benefit.
II. RULES OF LIABILITY
The determination of the legal rights, obligations, and limitations in-
volved in clinical investigation is complicated by the fact that special
law in this field is virtually nonexistent. The sources of legal rules, con-
stitutions, statutes, judicial decisions, and administrative decisions, rules,
and regulations provide with few exceptions, no special legal rules
for clinical investigation.
This does not mean, however, that clinical investigation is above the
law. There are general rules of law that do apply, and they certainly
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will be applied by the courts if litigation arises. The most significant
of these general rules are those relating to compensation for'personal
injury. Although it cannot be known with exactness how the courts
will adapt these general rules of liability to the unexplored field of
clinical investigation, the probable application of the rules can be fore-
seen with sufficient reliability to provide a practical guide for physicians
engaging in clinical investigation.
A. THE REQUIREMENT OF CONSENT
Perhaps the most important general rule of liability law to be con-
sidered is that relating to assault, that is, the rule that anyone who in-
tentionally takes any action which affects the body or mind of another
without the legally valid consent of that person is liable for damages,
unless there is a specific legal justification for that action.' To be an
effective defense against such liability, consent must be both voluntary
and informed.2
1. Informed Consent
Consent is not "informed" if the physician withholds information as
to either the risk involved in the treatment (or, if treatment is not had,
the nature of the treatment) or the results that may be reasonably ex-
pected, that is, the possibilities of successful treatment.3 These rules of
law should apply to clinical investigation situations, where the therapy
involved usually follows medically accepted, rather than unproven,
procedures.
As long as he is motivated by concern for his patient, the physician
may freely use his position of confidence and trust and his powers of
persuasion in urging his patient to agree to medically indicated treat-
ment.4 In exceptional circumstances recognized by standard medical
practice, the physician may even withhold information from the patient
which would otherwise be necessary in order to obtain an informed
1. See, e.g., Lowry v. Standard Oil Co., 63 Cal. App. 2d 1, 146 P.2d 57 (1944);
O'Brien v. Howell, 92 So. 2d 608 (Fla. 1957); Blankenship v. State, 130 Miss. 725, 95
So. 81 (1923); Mendenhall v. State, 18 Okla. Crim. 441, 196 P. 736 (1921). As to consent,
see Vanvactor v. State, 113 Ind. 276, 15 N.E. 341 (1888); Taylor v. State, 214 Md. 156,
133 A.2d 414 (1957). But see Wright v. Starr, 42 Nev. 441, 179 P. 877 (1919).
2. See, e.g., Guarro v. United States, 237 F.2d 578 (D.C. App. 1956).
3. See, e.g., Salgo v. Leland Stanford Jr. University Board of Trustees, 154 Cal. App.
2d 560, 317 P.2d 170 (1957); Natanson v. Kline, 186 Kan. 393, 350 P.2d 1093 (1960).
4. Hunt v. Bradshaw, 242 N.C. 517, 88 SYE.2d 762 (1955).
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consent.5 Obviously, in medical matters the physician and his patient
are not equals. In the ordinary case, the patient is entided to be in-
formed about his condition, the nature of the treatment proposed and
any unusual risks, and the results that may be anticipated.6 But in the
final analysis he will usually rely upon the advice and judgment of his
physician. If the information supplied is sufficient to serve as the basis
for the patient's informed consent, the physician may freely urge the
patient to submit to recommended treatment. What may be "accept-
able persuasion" as applied to medical treatment may be "undue in-
fluence," however, when applied to clinical investigation outside of the
physician-patient relationship.
Generally, physicians may be said to have a duty to inform. They
must explain a proposed procedure or therapy in lay terms so that the
patient has the opportunity to ask questions and come to a reasonable
understanding of the decision he is to make.1 In the normal course of
treatment, the physician is expected (1) to explain his diagnosis and prog-
nosis,8 (2) to describe in nontechnical terms the procedure or therapy
he proposes and explain any unusual hazard or risk of complications
that may be inherent in such procedure or therapy,9 and (3) to ex-
plain the results that may be reasonably anticipated, particularly if
the prospect for improving the patient's condition is limited.10 This
does not mean, however, that the physician must discuss with his pa-
tient remote possibilities of disaster if satisfactory results are normally
achieved uneventfully. 1
Medicine is both a science and an art, requiring the exercise of
technical skills within the framework of the personal relationship
between the physician and his patient. In the practice of his art, the
physician can inspire the confidence and tranquility of his patient
5. Watson v. Clutt, 262 N.C. 153, 136 S.E.2d 617 (1964); Roberts v. Wood, 206 F.
Supp. 579 (D.C. Ala. 1962); Grosjean v. Spencer, 140 N.W. 2d 139 (Iowa 1966); Ball
v. Mallinkrodt Chemical Works, 381 S.W.2d 563 (Tenn. 1964); Aiken v. Clary, 396
S.W.2d 668 (Mo. 1965); Fischer v. Wilmington General Hospital, 51 Del. 554, 149 A.2d
749 (1959); Hatcher v. Black, (a) Eddy, J. P.: Professional Negligence, London:
Stevens & Sons, Ltd. (1955). (b) Case Report, 2 BRmsH MEDICAL JOURNAL 105-106 (July
10, 1954).
6. Natanson v. Kline, supra note 3.
7. Mohr v. Williams, 95 Minn. 261, 194 N.W. 12 (1905); Block v. McVay, 80 S.D.
469, 126 N.W.2d 808 (1964).
8. Hunter v. Burroughs, 123 Va. 113, 96 S.E. 360 (1918); Rogers v. Lumbermen's
Mutual Casualty Company, 119 So.2d 649 (La. App. 1960).
9. Fritz v. Horsfall, 163 P.2d 148 (Wash. 1945).
10. Mitchell v. Robinson, 334 S.W.2d 11, 19 (Mo. 1960): Bolam v. Friern Hospital
(1957) 2 All E.R. 118.
11. Bang v. Charles T. Miller Hospital, 251 Minn. 427, 88 N.W.2d 186 (1958).
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even under discouraging circumstances. Compliance with the legal
requirements for informed consent need not keep the physician from
being compassionate in his patient relationships. His tone and manner
may freely express encouragement or a note of optimism for which
a basis exists in the patient's circumstances.
The need for an informed consent does not require a departure
from common sense standards of medical practice. Actually, the
physician's obligation has been judicially interpreted as a duty to
follow the standard of medical practice prevailing among reputable
physicians in the community as to the extent and kind of information
given to patients under similar circumstances. 2 It is customary for
the conscientious physician not only to inform but also to employ an
element of persuasion if this is in the best interest of the patient, such
as where the advantages of treatment clearly outweigh its risks. But
where there is a close or unknown balance between the possible bene-
fits and hazards of an inherently risky procedure, the physician's in-
fluence should be so tempered as to give the patient greater responsi-
bility in making his own decision.
Following standard medical practice means also that in exceptional
circumstances the patient need not be given the details about his con-
dition or proposed treatment."3 For example, it may be medically desir-
able and customary to withhold distressing information from a critically
ill cancer patient, or to avoid a frank explanation of proposed treatment
where the patient is so emotionally upset or disturbed that such an ex-
planation would cause him to decline clearly advisable treatment. Under
these circumstances, the physician should discuss the situation fully with
a member of the patient's immediate family or, if there is none, with a
friend who is concerned about the patient's well-being and informed
regarding his personal affairs. 4 This exception cannot be supported,
however, simply on the possibility that information necessary to permit
an informed consent might cause the patient to reject recommended
treatment on an entirely rational basis.' 5 If this justification were ac-
ceptable, it would practically dispense with the need for informed con-
sent and deprive the patient of the right which the courts are seeking
12. Wells v. McGehee, 39 So.2d 196 (La. App. 1949); Luka v. Lowrie, 171 Mich.
122, 136 N.W. 1106 (1912); Ollet v. Pittsburgh, Cincinnati, Chicago and St. Louis
Railway Company, 201 Pa. St. 361, 50 AtI. 1010 (1902); Jackovach v. Yocum, 212
Iowa 914, 237 N.W. 444 (1931).
13. Kennedy v. Parrott, 243 N.C. 355, 90 S.E.2d 754 (1956).
14. Natanson v. Kline, supra note 3.
15. Id.
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to protect, that is, the freedom to choose or decline treatment for
whatever reason the patient may have.
The duty to disclose is limited to those disclosures which a reason-
able chemical investigator would make under the same or similar circum-
stances. How he may best discharge his obligation to the subject in this
difficult situation involves primarily a question of medical judgment. His
choice of one of several plausible courses should not be called into ques-
tion if it appears, all circumstances considered, that he was motivated
only by the best interests of both the subject and medical science, and
that he proceeded as competent investigators would have done in a
similar situation.
The fundamental distinction between negligence and assault and
battery is that the former is unintentional and the latter intentional.
Thus where a subject consents to undergo clinical investigation, but
the nature, consequences, and risks of the investigation are not properly
explained to him, he may have a cause of action for assault. And where
a subject does give informed consent to undergo investigation, but is
injured as a result of lack of due care by the investigator, he has a cause
of action for negligence.
The clinical investigator is under a duty to inform the subject gen-
erally of the possible collateral hazards. He violates that duty and subjects
himself to liability, if he withholds from the subject any facts which
are necessary to form the basis of an intelligent consent to the proposed
investigation. Likewise, the investigator may not minimize the known
dangers of an investigation in order to induce the subject's consent. 16
The greater and more numerous risks, the greater the understanding
thereof that the courts will require. 17
"Caveat emptor"-let the buyer beware-still has much vitality in
business matters today, but it has no place in the law of the business
of medicine. Although in one sense the patient may be regarded as a
buyer of medical services, the courts place a great deal of responsibility
upon the physician because of the position of confidence and trust which
he occupies in relation to patients.' He is expected to explain his treat-
ment, anticipated results, and unusual risks, and at the same time to dedi-
cate himself to his patient's benefit. This becomes a legal tightqope when
16. Mitchell v. Robinson, supra note 10.
17. McCoid, A.H., Reappraisal of Liability for Unauthorized Medical Treatment, 41
MINN. LAW REv. 381, 427 (1957).
18. Yeates v. Harms, 193 Kan. 320, 393 P.2d 982 (1964); Valentine v. Kaiser Founda-
tion Hospitals, 15 Cal. Rptr. 26 (1961); Woods v. Brumlop, 71 N.M. 221, 377 P.2d 520
(1962).
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a frank explanation of hazards may serve to so upset an emotional patient
that he will choose the greater risk of declining treatment. The courts,
recognizing the physician's dilemma in such situations, have stated that
he should conduct himself according to the standard prevailing among
other reputable practitioners. 9 If the circumstances in particular cases
justify a lesser explanation of hazards in the interest of the patient, then
it would follow that experimentation with a human subject would
require a more thorough and objective explanation of risks than is nor-
mally required in medical treatment.
The question of how much information a physician must furnish
to a patient in order to avoid legal liability is somewhat confused be-
cause it arises out of two separate and distinct legal obligations. One is
the necessity to obtain valid consent. The other requires the physician
to act with the highest degree of good faith to protect the best in-
terests of the patient. Both obligations apply to clinical investigation
within the physician-patient relationship; but the second obligation does
not apply to clinical investigation outside of that relationship.
Thus it appears that the clinical investigator must always give the
minimum amount of information necessary to obtain valid consent. The
exception which permits the withholding of information for the benefit
of the patient does not apply in the clinical investigation situation. On
the other hand, where sufficient information has been given in order
to obtain valid consent, it would not appear that liability would arise
from a failure to give additional information to an investigative sub-
ject who is not a patient.
Consent by the patient must also be "voluntary." For instance, con-
sent is obviously lacking if a surgeon through error operates on the
wrong person, or amputates the wrong limb, or performs elective
surgery upon a patient who is informed only that he is to be examined
for purposes of diagnosis.20 Voluntary consent presupposes that the in-
dividual was supplied with sufficient information to enable him to make
a knowledgeable choice. Consent given in ignorance is not in any realistic
sense voluntary. However, consent cannot be deemed voluntary simply
because it was not obtained under force or duress. 21
19. See, e.g., Baldor v. Rogers, 81 So.2d 658 (Fla. 1954); Sinz v. Owens, 33 Cal.2d 749,
205 P.2d 3 (1949).
20. Fischer v. Wilmington General Hospital, supra note 5; Govin v. Hunter, 374
P.2d 421 (Wyo. 1962); Patrick v. Sedwick, 391 P.2d 453 (Alaska 1964).
21. Steele v. Woods, 327 S.W.2d 187 (Mo. 1959).
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2. Voluntary Consent
Although laymen are not ordinarily capable of the same understand-
ing about proposed medical treatment or experimentation as are phy-
sicians, they are not completely ignorant about medical procedures and
treatment. Considerable public interest and knowledge about medicine is
gained from newspapers, magazines, and ordinary schooling. There
is more common knowledge about medicine, its successes, and its fail-
ures than ever before. The courts have recognized that laymen are
capable of understanding in general terms such matters as the results
that may be reasonably expected from treatment and the degree of
risk to life or health that may be involved.22 On the other hand, the
courts have laid down the rule that an individual cannot be deemed to
have voluntarily consented to treatment about which he knows little
or nothing.23 "Voluntary" consent is thus closely related to "informed"
consent. But there is voluntary consent when there is freedom to
choose with understanding; that is, voluntary consent arises out of an
unrestricted freedom to choose and a reasonable understanding of the
choices available.24
3. Constructive Consent
In emergencies, where the patient is unconscious or irrational and
there is no other person available who is legally authorized to approve
treatment, "constructive" consent may be implied from the circum-
stances.25 The physician's authority to proceed with treatment is based
upon the presumption that the patient would have consented to treat-
ment necessary to protect his life or health if he had been able to do
so. 2 This is an exception to the physician's legal duty to obtain consent
prior to treatment.
4. Capacity to Consent
The validity of consent also depends upon the legal capacity or au-
thority of the person who gives the consent. It is generally recognized
that infants or persons suffering from general mental incompetence are
22. Mitchell v. Robinson, supra note 10.
23. Hunt v. Bradshaw, supra note 4; Patrick v. Sedwick, supra note 20.
24. Salgo v. Leland Stanford Jr. University University Board of Trustees, supra
note 3.
25. Regan, L. J., Doctor and Patient and the Law 41 (3rd Ed. 1956).
26. Moritz, A. R. and Stetler, C. J., Handbook of Legal Medicine 151 (2nd Ed. 1964).
WILLIAM AND MARY LAW REVIEW
not legally capable of giving consent on any subject.27 Competence
to give consent is not necessarily an all or nothing situation. Some
persons may be legally capable of giving consent for some purposes,
but not for all." To whatever extent a person is incapable of giving con-
sent, the law grants to some other person the authority to act for him,
at least for limited purposes. 29
If the subject has been committed to a mental institution or certified
as laboring under a legally recognized mental aberation and is therefore
(to use the Illinois designation for the purpose of illustration) a legally
insane person, a sexually dangerous person (a criminal sexual psycho-
pathic person), a criminal mentally incompetent person, a person in
need of mental treatment, or a mentally retarded person, then, of
course, consent could not be obtained for the subject. In such a
situation consent should be obtained from both parties in loco parentis
-the individual and the institution. If the subject is married, the in-
dividual would be the spouse.31 If the subject is unmarried, the individ-
ual would be the closest next of kin.32 For the ascertainment of the
closest of kin, a good "rule of thumb" to follow is the order of priorities
contained in the particular state's law of descent and distribution.
The consent of the individual is of a higher nature and, consequently,
of more importance than the consent of the institution. This is so be-
cause, from a legal point of view, the subject-individual relationship is
analogous to the concept of possession, whereas the subject-institution
relationship is analogous to the lesser concept of custody. Again
analogously, and again from a legalistic standpoint, the seat of the sub-
ject-individual relationship is akin to the concept of domicile, whereas
the seat of the subject-institution relationship is akin to the concept
of residence. Therefore, the ostensibly informed consent of the indi-
vidual would be subjected to an even greater degree of legal scrutiny
than the purported informed consent of the institution.
If the subject has not been committed or certified to be laboring
under a legally recognized mental disability, his consent, of course, must
be first obtained. If the subject is a prisoner, three consents should be
27. Zoski v. Gaines, 271 Mich. 1, 260 N.W. 99 (1935).
28. Lacey v. Laird, 166 Ohio St. 12, 139 N.W.2d 25 (1956).
29. Crippen v. Pulliam, 61 Wash.2d 725, 380 P.2d 475 (1963).
30. Farber v. Olkon, 246 P.2d 710 (Cal. App. 1952), aff'd 40 Cal.2d 503, 254 P.2d
520 (1953).
31. Lester v. Aetna Casualty and Surety Company, 240 F.2d 676 (5th Cit. 1957).
32. Farber v. Olkon, supra note 30.
33. Crippen v. Pulliam, supra note 29.
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obtained-from the prisoner, his spouse (otherwise, his nearest of kin),
and the institution.
The courts made it clear that a child is not the property of its
parents and may not be dealt with without regard for his best in-
terests. 4 In a number of cases, for example, the courts have intervened
to order medically indicated blood transfusions over the objection of
the child's parents.35
If a parent or guardian agrees to a minor's participation in clinical
investigation outside of the physician-patient relationship that is not
hazardous in terms of life, health, pain, or suffering, and if injury does
not occur, the likelihood of legal problems is remote. Here, the issue of
legal consent is, more or less, academic. Where the possibility of danger
to the minor's life or health is not remote, the legal issue of consent
cannot be brushed aside so easily.
A parent or guardian has an obligation to act in the child's best interests
and for his benefit.36 Accordingly, consent can be given on behalf of
the child for medically indicated treatment.3 7 The parental responsibility
may be violated, though, if a parent or guardian exposes the child to un-
necessary danger.38 Consequently, the parent's consent to the use of a
child for clinical investigation that is not medically indicated for the
benefit of the child may be of doubtful validity as a defense against a
liability claim. Illness or injury may justify appropriate but unproven
therapy if other procedures are unsatisfactory. But clinical investiga-
tion not for the purpose of treating the child cannot be assumed to be
for the child's benefit simply because the child might later have the
"satisfaction" or "reward" of participating in medical progress.
Although a number of courts have said that a minor who has reached
the age of sufficient understanding (the so-called age of discretion) can
consent to medically indicated treatment; 9 it is questionable whether
the courts would take the same position with respect to his participation
in clinical investigation. It is likely that a court would regard submission
34. See, e.g., Pierce v. Jeffries, 103 W.Va. 410, 139 S.E. 651 (1927); Denton v. James,
107 Kan. 729, 193 P. 307 (1920).
35. State v. Perricone, 37 N.J. 463, 181 A.2d 751 (1962).
36. Rubenstein, I. H., A Treatise on Contemporary Religious jurisprudence 43, 44
(1948).
37. People v. Pierson, 176 N.Y. 201, 68 N.E. 243 (1903).
38. Owens v. State, 6 Old. Cr. 110, 116 P. 345 (1911); Mitchell v. Davis, 205 S.W.2d
812 (Tex. Cr. 1947).
39. Gulf and Ship Island Railroad v. Sullivan, 155 Miss. 1, 119 So. 501 (1928); Lacey v.
Laird, supra note 28; Sullivan v. Montgomery, 279 N.Y.S. 575 (1935).
1967]
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to clinical treatment as a reasonable area for the decision of a mature
minor, and that doubt concerning capacity to consent would be re-
solved in favor of the child acting for his own benefit.
The courts generally allow minors to make their own decisions in
business and property matters only when such freedom is consistent
with their own well-being and public policy.40 Inasmuch as the courts
give greater protection to life and health than to property rights,4 ' they
may ordinarily be expected to regard voluntary participation in clinical
investigation involving hazard as a privilege reserved only for adults.
One medical authority in England has said: "It is clearly within
the competence of a parent or guardian of a child to give permission
for procedures intended to benefit that child when he is not old or
intelligent enough to be able himself to give a valid consent. In the
strict view of the law parents and guardians of minors cannot give
consent on their behalf to any procedures which are of no particular
benefit to them and which may carry some risk of harm. The reality
of any purported consent which may have been obtained is a question
of fact, and as with an adult the evidence would, if necessary, have
to show that irrespective of age the person concerned fully under-
stood the implications to himself of the procedures to which he was
consenting. In the case of children and young persons the question
whether purported consent was true consent would in each case de-
pend upon facts such as age, intelligence, situation, and character of
the subject, and the nature of the investigation." 42
The general rule concerning consent in respect to a surgical opera-
tion on a child was stated in 1941 by the United States Court of Ap-
peals for the District of Columbia in Bonner v. Moran. It probably
has equal application to consent in respect to a child's participation in
clinical investigation. The rule was stated as follows:
"In deference to common experience, there is general recognition of
the fact that many persons by reason of their youth are incapable of
intelligent decision, as the result of which public policy demands legal
protection of their personal as well as their property rights. Hence it
is not at all surprising that, generally speaking, the rule has been
40. Carolina Telephone and Telegraph Company, Inc. v. Johnson 168 F.2d 489 (4th
Cir. 1948).
41. Application of Sacer Realty Corporation, 73 N.Y.S.2d 211 (1947).
42. "Responsibility in Investigations on Human Subjects-Statement by Medical Re-
search Council," BRnsH Mwxcm JouRNAL, 178, 179 (July, 1964).
43. 75 U.S. App. D.C. 156, 126 F.2d 121 (1941).
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considered to be that a surgeon has no legal right to operate upon a
child without the consent of his parents or guardian. There are, of
course, exceptions to the rule. One of them is in cases of emergency,
when obviously an operation is necessary ... others perhaps in cases
in which the child has been emancipated, or where the parents are so
remote as to make impracticable the obtaining of their consent in
time to accomplish proper results. And where the child is close to
maturity, it has been held that the surgeon may be justified in ac-
cepting his consent. But in all such cases the basic consideration is
whether the proposed operation is for the benefit of the child and is
done with a purpose of saving his life or limb.44
Outside of the physician-patient relationship, it is clear that persons
lacking capacity to consent should not be used for clinical investiga-
tion merely because they are convenient or available. It is recognized,
however, that in some instances the advancement of medical science
would be impossible without the use of persons of this class as investi-
gative subjects. Some kinds of clinical investigation of children's diseases
cannot be accomplished without using children as subjects. Similarly,
necessary research on mental retardation might be impossible without
the participation of mentally retarded subjects. It seems unlikely that
public policy would entirely foreclose clinical investigation in these
fields outside of the physician-patient relationship. There would, of
course, never be any justification for the use of subjects who lack
capacity to consent if the data sought could be obtained by using mentally
competent adult subjects. It is also doubtful that it would ever be
justifiable to subject children to the same degree of risks as would be
permissible in the case of mentally competent adult subjects or of
patients for whom possible benefits might offset the risks.
It is likely that some mechanism will eventually be developed to
provide authorization for the participation of subjects who lack the
capacity to consent in clinical investigation outside of the physician-
patient relationship, under appropriate limitations and with adequate
safeguards. At present, however, there is no recognized proce-
dure for establishing a defense against liability for unauthorized
investigation of this type. The clinical investigator can minimize the
legal risk by limiting the use of such subjects to situations in which
there is the strongest scientific justification and the, minimum of risk
of injury.
44. 75 U.S. App. D.C. 156, 126 F.2d 121, 122, 123 (1941).
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B. THE DUTY TO EXERCISE REASONABLE CARE
Another important principle of law is the general rule that a person
is liable for damages when his negligence has caused injury to the
person or property of another.45 Negligence is the failure to conform
to the standard of reasonable care.46 In the physician-patient relation-
ship the physician is expected to possess and exercise that degree of
skill and care ordinarily possessed and exercised by physicians in good
standing in similar circumstances.4 7 This standard applies where clinical
investigation is conducted within the physician-patient relationship.
Where it is conducted outside of that relationship, it is likely that the
applicable standard would be that of the reasonable and prudent
clinical investigator; the investigator would be required to possess and
exercise that degree of skill and care that is ordinarily possessed and
exercised by clinical investigators under similar circumstances. In neither
case would liability arise unless a failure to conform to the respective
standards was the proximate cause of injury to the patient or the
subject.48
In clinical investigation, negligence may consist of errors in pro-
cedure or technique, as it would in other forms of activity. It may
also consist, however, of exposure of the patient or subject to unneces-
sary or unwarranted risks of failure to provide adequate safeguards
by departing from the respective standards of care.
There are many judicial decisions on the issue of professional negli-
gence in the physician-patient relationship.49 These would apply gen-
45. See, e.g., Stone v. Proctor, 259 N.C. 633, 131 S.E.2d 297 (1963). Standard Oil
Compnay v. Southern Pacific Company, 268 U.S. 146 (1925); Turlington v. Tampa
Electric Company, 62 Fla. 398, 56 So. 696 (1911); Patten v. Bartlett, 111 Me. 409, 89
At. 375 (1914); West Virginia Central and Pittsburg Railway Company v. State, 96
Ad. 652, 54 At. 669 (1903); Loso v. Lancaster County, 77 Neb. 466, 109 N.W. 752
(1906).
46. Shearman, Thomas G. and Redfield, Amasa A., A Treatise on the Law of Negli-
gence 7 (1941).
47. Cusumano, Charles L., Malpractice Law Dissected for Quick Grasping 35 (1962).
48. 3 Shearman, Thomas G. and Redfield, Amasa A., A Treatise on the Law of
Negligence 1527, 1528 (1941).
49. Goodwin v. Hertzberg, 201 F.2d 204 (D.C. Cir. 1952) (perforation of woman's
urethra in performance of operation); Lawrence v. Nutter, 203 F.2d 540 (4th Cir. 1953)
(failure of physician to administer gas gangrene antitoxin); Moore v. Belt, 34 Cal.2d
525, 212 P.2d 509 (1950) (cause of infection of urinary passages resulting from genito-
urinary examination); Nielsen v. Milligan, 100 Cal App.2d 40, 222 P.2d 916 (1950) (fail-
ure to check infection when it first developed); Huffman v. Lindquist, 37 Cal.2d 465,
234 P.2d 34 (1951) (nonsurgical treatment of brain injury); Merkle v. Kegerreis, 350
Ill. App. 103, 112 N.E.2d 175 (1953) (negligence of roentgenologist in removing plantar
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erally, of course, to clinical investigation within that relationship. None
of them relate specifically to clinical investigation as defined herein,
either within or without the physician-patient relationship.
Usually, clinical investigation involves departures from generally
accepted procedures for diagnosis or therapy. Not every instance of
departure from such generally accepted procedures constitutes clinical
investigation, however. To achieve that status, the departure must be
a part of a systematic program for the advancement of scientific
medical knowledge. The cultist practitioner who has a mistaken and
scientifically unsupported belief in the efficacy of a special procedure
is not engaged in clinical investigation when he applies that procedure
to a patient. The conscientious physician who tries an unproved but
promising therapy solely for the benefit of his patient, without engag-
ing in any systematic collection of data is likewise not engaged in
clinical investigation. A few cases involving these types of departures
from accepted forms of therapy have reached the courts.=° Some of
the opinions contain references to clinical investigation and appear to
convey the impression that such investigation can be carried on only
at the risk of the investigator. The context of these decisions makes it
doubtful, however, that this impression was intended. In any event, it is
highly unlikely that courts would take such an extreme position today.
The significance of the case law in this area should nevertheless be
examined and evaluated. In Carpenter v. Blake5l in 1871 the Supreme
Court of New York declared:
"It is incumbent on surgeons to treat such an injury to conform
to the system thus established; and if they depart from it, they do it
at their peril. Before the new practice can be used to shield the
surgeon from the charge of malpractice, it must appear that the cases
in which it was tested were substantially the same as those treated
by (other authorities) and that the treatment thus resorted to has
been successful in so many instances as to establish satisfactorily the
propriety and safety of adopting it."
wart from ball of foot); Stickleman v. Synhorst, 243 Iowa 872, 52 N.W.2d 504 (1952)
(negligence in injecting oil into patient's trachea in lung mapping process causing ex-
cessive loss of blood); Bradshaw v. Wilson, 87 Ohio App. 319, 94 N.E.2d 706 (1950)
(failure of orthopedic surgeon to properly reduce fracture of arm); Frederickson v.
Maw, 119 Utah 385, 227 P.2d 772 (1951) (negligence of physician leaving part of
surgical sponge in wound); Madis v. Stellwagen, 38 Wash.2d 1,227 P.2d 445 (1951)
(failure to remove needle in eye operation).
50. Hunter v. Burroughs, supra note 8. Natanson v. Kline, supra note 6.
51. 60 Barb. (N.Y.) 488 (1871), rev'd on other grounds, 50 N.Y. 696 (1872).
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The first sentence indicates a strong disposition on the part of the
jurists to carry over the stultifying effect of a strict adherence to
stare decisis to their medical brethren. The second sentence repre-
sents a classic example of circular reasoning by the judiciary. How
can a new practice have been successful in prior instances unless it is
used initially? How can a surgeon acquire experience in administering
a new treatment without inaugurating such treatment? The second
sentence overlooks the obvious fact that some human being some-
where must necessarily be the first one upon whom a medical tech-
nique is tried or to whom a new medicine is administered. A literal
compliance with the second sentence would stifle to the point of
stymieing medical innovation and consequent advancement. Clearly, in
Ca'penter the trial of an unproven procedure was confused with a
failure to adhere to the community standard.
In Langford v. Kosterlitz52 in 1930 the District Court of Appeal of
California ruled that subjecting a patient to unproven therapy without
disclosure and consent is contrary to the custom of physicians, and
thus constitutes negligence even though there was no technical error
in the actual performance of the procedure. It is apparent that by 1930
there was an absolute judicial insistence on informed consent as a
condition precedent to unproven procedures.
In Fortner v. Koch 3 in 1935 the Supreme Court of Michigan de-
clared: "If the general practice of medicine and surgery is to progress,
there must be a certain amount of experimentation carried on; but
such experimentation must be done with the knowledge and consent
of the patient or those responsible for him and must not vary too
radically from the accepted methods of practice." Fortner is of special
significance for here the court was not merely condoning but was
actually encouraging the trial of unproven procedures. The first phrase
of the quoted sentence should be considered and treated as a judicial
policy statement. The last phrase of the quoted sentence contains three
important points. The first of these repeats the insistence of Langford
on informed consent as a prerequisite to such procedures. The sec-
ond point raises the very significant and difficult problem, to be dis-
cussed and analyzed later in this paper, of whether one in loco parentis
to a subject may give effective consent for the administration of an
unproven procedure and, if so, under what legal disability must the
subject be laboring and what must the loco parentis relationship be.
52. 107 Cal. App. 175, 290 P. 80 (1930).
53. 272 Mich. 273, 261 N.W. 762 (1935).
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The third point projects the element of extent into the picture, that
is, how far may the unproven procedure vary from the traditional
methods-what, in short, is the degree of tolerance.
Similar misapprehension is sometimes created by extrajudicial state-
ments on medical experiments. An example is the following statement
by Claude Bernard:
"As far as direct applicability to medical practice is concerned, it
is quite certain that experiments made on man are always the most
conclusive. No one has ever denied it. First, have we a right to per-
form experiments and vivisections on man? Physicians make thera-
peutic experiments daily on their patients, and surgeons perform
vivisections daily on their subjects. Experiments, then, may be per-
formed on man, but within what limits? It is our duty and our right to
perform an experiment on man whenever it can save his life, cure him,
or gain him some personal benefit. The principle of medical and
surgical morality, therefore, consists in never performing on man an
experiment which might be harmful to him to any extent, even though
the result might be highly advantageous to science, i.e., to the health
of others. But performing experiments and operations exclusively from
the point of view of the patient's own advantage does not prevent
their turning out profitably to science." 54
In actual litigation, the standard for protection from liability will
undoubtedly be what the court or the jury believes to be the prevailing
standard of reasonable care. A prevailing practice of following an in-
adequate standard of care will not necessarily afford a defense for
liability is always tested by whether or not there was a failure to exer-
cise reasonable care.
Research institutions have established high standards for clinical in-
vestigation, both within and without the physician-patient relationship.
Other means of investigation are always exhausted before investigation
with human beings is attempted. Subjects and patients are kept under
close and frequent observation, and the investigation is terminated
whenever adverse effects are detected. Research is conducted by teams
of physicians and scientists who represent a wide spectrum of skills
and who are trained in clinical investigation. Unless the physician
in private practice can match the skill, care, and safeguards
54. Bernard, Claude, cited by Bean, William B., M.D.: "Testament of Duty: Some
Strictures on Moral Responsibilities in Clinical Research," Journal of Laboratory and
CLINICAL MEDICINE, 3-9 (January, 1952).
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provided in research institutions, he may be in a precarious position of
legal liability if he attempts a radical form of unproven therapy. The
skilled practicing physician is not necessarily a capable clinical in-
vestigator at all levels of investigation. No physician should under-
take investigation beyond his level of competence.
III. STANDARDS DERIVED FROM COLLATERAL SOURCES
Specific legal authority concerning the details of what clinical in-
vestigators should or should not do to avoid liability is not available.
Certain collateral sources which may offer some guidance in judging
what is proper conduct are available, however.
A. THE FEDERAL FOOD, DRUG AND COSMETIC AcT
One possible source is section 505 of the Federal Food, Drug
and Cosmetic ActY It prohibits the introduction of any new
drug into interstate commerce unless it is first accepted as safe and
effective by the Food and Drug Administration. Regulations must be
promulagted exempting from this prohibition "drugs intended solely
for investigational use by experts qualified by scientific training and
experience to investigate the safety and effectiveness of drugs," and
such regulations must "provide that such exemption shall be con-
ditioned upon the manufacturer, or the sponsor of the investigation,
requiring that experts using such drugs for investigational purposes
certify to such manufacturer or sponsor that they will inform any
human beings to whom such drug, or any controls used in connec-
tion therewith, are being administered, or their representatives, that
such drugs are being used for investigational purposes and will obtain
the consent of such human beings or their representatives, except where
they deem it not feasible or, in their professional judgment, contrary
to the best interest of such human beings."
The Food and Drug Administration has issued a Statement of Policy,56
interpreting these provisions of the statute, as follows:
(a) Section 505 (i) of the act provides that regulations on use of
investigational new drugs on human beings shall impose the condition
that investigators "obtain the consent of such human beings or their
representatives, except where they deem it not feasible or, in their
professional judgment contrary to the best interest of such human
55. 21 U.S.C.A., sec. 355 (1961).
56. 21 C.F.R. 130.36 (1966).
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beings." (b) This means that the consent of such human beings (or
the consent of their respresentatives) to whom investigational drugs
are administered primarily for the accumulation of scientific knowl-
edge, for such purposes as studying drug behavior, body processes,
or the course of a disease, must be obtained in all cases and, in all but
exceptional cases, the consent of patients under treatment with investi-
gational drugs must be obtained. (c) "Under treatment" applies when
the administration of the investigational drug for either diagnostic or
therapeutic purposes constitutes responsible medical judgment, taking
into account the availability of other remedies or drugs and the indi-
vidual circumstances pertaining to the person to whom the investiga-
tional drug is to be administered. (d) "Exceptional cases," as used in
paragraph (b) of this section, which exceptions are to be strictly ap-
plied, are cases where it is not feasible to obtain the patient's consent or
the consent of his representative, or where, as a matter of professional
judgment exercised in the best interest of a particular patient under
the investigator's care, it would be contrary to that patient's welfare
to obtain his consent. (e) "Patient" means a person under treatment.
(f) "Not feasible" is limited to cases where the investigator is not
capable of obtaining consent because of inability to communicate with
the patient or his representative; for example, where the patient is
in a coma or is otherwise incapable of giving informed consent, his
representative cannot be reached, and it is imperative to administer the
drug without delay. (g) "Contrary to the best interests of such human
beings" applies when the communication of information to obtain
consent would seriously affect the patient's disease status and the
physician has exercised a professional judgment that under the partic-
ular circumstances of this patient's case, the patient's best interests
would suffer if consent were sought. (h) "Consent" or "informed
consent" means that the person involved has legal capacity to give
consent, is so situated as to be able to exercise free power of choice,
and is provided with a fair explanation of all material information con-
cerning the administration of the investigational drug, or his possible
use as a control, as to enable him to make an understanding decision
as to his willingness to receive said investigational drug. This latter
element requires that before the acceptance of an affirmative decision
by such person the investigator should make known to him the nature,
duration, and purpose of the administration of said investigational
drug; the method and means by which it is to be administered; all in-
conveniences and hazards reasonably to be expected, including the
fact, where applicable, that the person may be used as a control; the
existence of alternative forms of therapy, if any; and the effects upon
his health or person that may possibly come from the administration
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of the investigational drug. Said patient's consent shall be obtained
in writing by the investigator.
It should be noted that the statute and policy statement technically
relate only to the introduction into interstate commerce of a new drug
intended solely for investigational use. In form, at least, it is a legal
limitation on manufacturers or others who would introduce a drug
into interstate commerce, not a limitation on clinical investigators. It
has no application to clinical investigation of drugs not introduced into
interstate commerce or to clinical investigation not related to drugs. It
does not directly impose any duty on clinical investigators, although
it has the effect of barring clinical investigation involving a new drug
for introduction into interstate commerce where the investigators have
not given the required information or obtained the required consent.
It is obvious, however, that the primary if not the only reason why
Congress included these provisions in the statute was to protect those
human beings who participate in clinical investigation of drugs either
within or without the physician-patient relationship. For that reason,
the statutory provisions and the policy statement tend to establish
minimum standards for clinical investigators. These standards would
not necessarily apply in litigation concerning legal liability, but they do
furnish some guide to the standards that might be applied.
Other statutory provisions which have a bearing on clinical investi-
gation are found in state statutes which permit prisoners to volunteer
for medical research. In Iowa, the prisoner must volunteer in writing
and may withdraw his consent at any time.57 In Virginia, prisoners
are permitted to participate in medical research under regulations pre-
scribed by the State Board of Prisons."
B. INSISTENCE ON WRITTEN INFORMED CONSENT BY
HOSPITAL ADMINISTRATORS
Collateral guidance may also be obtained from some court de-
cisions not related to liability. One arose out of a cancer research pro-
gram in a private hospital in New York 9 A substance derived from
cancer cells was injected into chronically ill patients, who were told
that they would receive a harmless substance which might cause a
57. IOWA CODE ANN., sec. 246-47 (1946).
58. VA. CODE ANN., 53-57.1 (1950).
59. Hyman v. Jewish Chronic Disease Hospital, 21 A.D.2d 495, 251 N.Y.S.2d 818
(1964), reversed 15 N.Y.2d 317, 258 N.Y.S.2d 397, 206 N.E.2d 338 (1965).
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slight discomfort. Only oral consent had been obtained. Litigation
arose out of the efforts of one member of the hospital's board of
directors to get information from the hospital records concerning this
program.
In this 1964 case, Hyman v. Jewish Chronic Disease Hospital,60 the
Appellate Division of the Supreme Court of New York stated:
"The Hospital's future policy will be in accordance with petitioner's
contention that experiments such as the one here involved should be
done only with the patient's written consent after the patient has been
properly informed. On September 7, 1963, the Hospital's Grievance
Committee approved the experiment. On September 30, 1963, its board
of directors approved its Grievance Committee's report. On January
27, 1964, the Hospital's Research Committee approved continuance of
the cancer immunization studies, but only upon the written, informed
consents of the patients. Here we have judicial insistence not only on
informed consent but on "'written, informed" consent, the court stat-
ing "that experiments should be done only with the patient's written
consent after the patient has been properly informed."
Hyman was reversed on appeal by the Court of Appeals of New
York,"' but on a ground unrelated to the propriety of clinical investiga-
tion. Stemming from this litigation, as the Court of Appeals pointed
out, the board of directors "merely enacted rules of the hospital (which)
now require that written and informed consents of the patients be ob-
tained before experiment."
C. ETHICAL STANDARDS DEVELOPED BY THE MEDICAL PROFESSION
Also of some assistance in delineating reasonable standards for clinical
investigation are certain ethical standards which have been developed
by the medical profession.
1. Nuremberg Code
The most important of these perhaps is the so-called "Nuremberg
Code." 62 Early in 1946 the Allied Military Tribunal was preparing for
60. 21 A.D.2d 495, 499, 251 N.Y.S.2d 818, 822 (1964).
61. 15 N.Y.2d 317, 258 N.Y.S.2d 397, 399, 206 NE.2d 338, 339 (1965).
62. U.S. GOVERNMENT PRINTING OFFIcE, 2 UNITED STATES V. BRANDT, ET AL., TRIALS OF
WAR CRIMINALS BEFORE NUREMBERG MILITARY TRIBUNALS, OCTOBER, 1946-APRIL, 1949, 194
(1950).
1967]
WILLIAM AND MARY LAW REVIEW
the trials of twenty-three Nazi physicians and scientists charged with
demoniacal and diabolical experiments on political prisoners. At the
requests of the Secretary of State and the Secretary of War, the Amer-
ican Medical Association appointed Dr. Andrew C. Ivy, to serve as an
advisor to the prosecuting attorneys on the ethics of medical research.
Dr. Ivy, with the assistance of other physicians drafted an outline of
ten principles of ethics governing the use of human subjects in medical
research. These principles, with slight amendment, were presented dur-
ing the trials by General Telford Taylor as the cornerstone of the
allied case against the Nazi physicians. The opinions of the Military Tri-
bunal adopted these principles as a ten-point judicial summary of the
expert medical testimony presented principally by the prosecution.
The ten points of the Nuremberg Code are as follows:
1. The voluntary consent of the human subject is absolutely essential.
2. The experiment should be such as to yield fruitful results for the
good of society, unprocurable by other methods or means of
study, and not random and unnecessary in nature.
3. The experiments should be so designed and based on the results
of animal experimentation and a knowledge of the natural history
of the disease or other problem under study that the anticipated
results will justify the performance of the experiment.
4. The experiment should be so conducted as to avoid all unneces-
sary physical and mental suffering and injury.
5. No experiment should be conducted where there is an a priori
reason to believe that death or disabling injury will occur; ex-
cept, perhaps, in those experiments where the experimental phy-
sicians also serve as subjects.
6. The degree of risk to be taken should never exceed that deter-
mined by the humanitarian importance of the problem to be solved
by the experiment.
7. Proper preparations should be made and adequate facilities pro-
vided to protect the experimental subject against even remote
possibilities of injury, disability, or death.
8. The experiment should be conducted only by scientifically quali-
fied persons. The highest degree of skill and care should be re-
quired through all stages of the experiment of those who conduct
or engage in the experiment.
9. During the course of the experiment the human subject should be
at liberty to bring the experiment to an end if he has reached the
physical or mental state where continuation of the experiment
seems to him to be impossible.
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10. During the course of the experiment the scientist in charge must
be prepared to terminate the experiment at any stage, if he has
probable cause to believe, in the exercise of good faith, superior
skill and careful judgment required of him that a continuation of
the experiment is likely to result in injury, disability, or death
to the experimental subject.
The phrase "voluntary consent" in Point No. 1 of the Nuremberg
Code means informed consent as well. This can be determined from
the elaborate definition of voluntary consent which accompanied Point
No. 1:
"This means that the person involved should have legal capacity
to give consent; should be so situated as to be able to exercise free
power of choice, without the intervention of any element of force,
fraud, deceit, duress, overreaching, or other ulterior form of constraint
or coercion; and should have sufficient knowledge and comprehension
of the elements of the subject matter involved as to enable him to make
an understanding and enlightened decision. This latter element requires
that before the acceptance of an affirmative decision by the experi-
mental subject there should be made known to him the nature, dura-
tion, and purpose of the experiment; the method and means by which
it is to be conducted; all inconveniences and hazards reasonably to be
expected; and the effects upon his health or person which may possibly
come from his participation in the experiment. The duty and responsi-
bility for ascertaining the quality of the consent rests upon each in-
dividual who initiates, directs, or engages in the experiment. It is
a personal duty and responsibility which may not be delegated to an-
other with impunity." 63
In respect to Point No. 2 of the Nuremberg Code, it may be dan-
gerous to suggest that an experiment which might otherwise be un-
justifiable is justified because it is for the common good. Any clinical
investigator can claim that what he is doing is for the good of society.
Certainly an increased risk must never be accepted simply because
the project is believed to be of great importance or value to the com-
munity. More important considerations than the possible value of a
clinical investigation are:
(1) whether it is well conceived and planned,
63. U.S. GOVERNMENT PRINTING OFFICE, 2 UNITED STATES V. BRANDT, ET AL., TRIALS OF
WAR CRIMINALS BEFORE NUREMBERG MILITARY TRIBUNALS, OCTOBER, 1946-APRIL, 1949, 194
(1950).
WILLIAM AND MARY LAW REVIEW
(2) whether thought has gone into the framing of hypotheses to be
tested,
(3) whether the experiment is designed to answer the questions posed,
(4) whether the same information could be equally well obtained by
experiments on laboratory animals, and
(5) whether the clinician has the skill and knowledge necessary to
conduct the investigation properly.
In connection with Point No. 9 of the Nuremberg Code, it is in-
teresting to note that Barney G. Glaser and Anselm L. Strauss, in their
Awareness of Dying, make the following observation:
"A basic principle in clinical research is that a subject should be
allowed to withdraw when he feels that continuation is mentally and
physically impossible, however, this rule is often not the operating
criteria for deciding on a withdrawal. It is easy enough to say that
the patient in his distraught condition is not mentally capable of decid-
ing whether he is mentally and physically capable of continuing. It
must, therefore, be decided for him (!) by family or the doctor, and
thus the patient loses this apparent control." 11
It is apparent that the Nuremberg Code has an unusual status-it was
drafted primarily for the purpose of a war crime trial, yet it was in-
tended to be a statement of ethical principles for clinical investigation.
There is no doubt that anyone in the United States who engaged in
experiments similar to those disclosed in the Nuremberg trial would be
convicted under existing criminal laws, that is, there would be no need
to refer to the code. It should be noted, however, that in the Nurem-
berg trial in no instance was the guilt of an accused based solely upon
a failure to give sufficient information to the experimental subject in
obtaining his consent.
2. Principles of Medical Ethics
The significance attached to the Nuremberg Code was reflected in a
report of the Judicial Council adopted by the House of Delegates of
the American Medical Association in December of 1946.6 According
64. Glaser, B. G. and Strauss, A. L., AWARENESS OF DYING 192 (1965).
65. The proceedings of the San Francisco, 1946, session of the House of Delegates of
the American Medical Association contain a resolution presented by Robertson Ward,
M.D., of California, directing the appropriate committee or council of AMA to review,
clarify, and recommend to the next session of the House such revisions in the Principles
[Vol. 8:359
1967] LEGAL IMPLICATIONS OF CLINICAL INVESTIGATION 381
to this report, in order to conform to the Principles of Medical Ethics
of the AMA, the following requirements for clinical investigations on
human beings must be satisfied:
1. The voluntary consent of the person on whom the experiment is
to be performed must be obtained;
of Medical Ethics as may be found necessary and advisable. The Judicial Council sat
as a reference committee to consider this resolution and recommended its approval and
requested that it be permitted to include its findings in its annual report to the House
at the Annual Session in 1947.
The proceedings of the Chicago, 1946, session of the House of Delegates reflect that
R. L. Sensenich, MD., Chairman of the Board of Trustees, submitted the following
report:
"The Department of State of the federal government several months ago re-
quested the American Medical Association to suggest the name of an outstanding
medical investigator to represent the United States on an inter-allied commission
to study the medical experiments on human beings carried on by the Nazi gov-
ernment during the war. The Board of Trustees selected Dr. A. C. Ivy of Chicago
as the representative. Dr. Ivy went to Europe and on his return submitted a
report to the government and a copy to the Board of Trustees. The Board
referred the report to the Judicial Council, and it is expected that the Council
will report to the House of Delegates its conclusions and recommendations."
E. R. Conniffe, MD., Chairman of the Judicial Council, presented the following
report of the Council:
"This supplementary report concerns the report made by Dr. A. C. Ivy, who
was sent to Europe as a representative of the United States Government to review
the war crimes of a medical nature committed by the Germans, which report
was referred to the Executive Committee of the Board of Trustees, which in
turn referred the matter to the Judicial Council."
"The Council finds that the experiments described in Dr. Ivy's report are abso-
lutely opposed to the Principles of Medical Ethics of the American Medical As-
sociation and are to be condemned. In order to conform to the ethics of the
American Medical Association, three requirements must be satisfied: (1) the
voluntary consent of the person on whom the experiment is to be performed;
(2) the danger of each experiment must be previously investigated by animal ex-
perimentation; and (3) the experiment must be performed under proper medical
protection and management."
This report was referred to the Reference Committee on Miscellaneous Business.
The report of the Reference Committee on Miscellaneous Business contains the fol-
lowing statement:
"Your Reference Committee finds that the experiments described in Doctor
Ivy's report are opposed to the Principles of Medical Ethics of the American
Medical Association, which have three basic requirements: 1. The voluntary
consent of the individual on whom the experiment is to be performed must be
obtained; 2. The danger of each experiment must be previously investigated by
animal experimentation, and 3. The experiment must be performed under proper
medical protection and management."
When this section of the Reference Committee report was presented, it was carried
after an amendment suggested by Edward P. Flood, MD., and seconded by James C.
Sargent, M.D., was withdrawn following discussion by Holman Taylor, MD, and
Morris Fishbein, M.D.
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2. The danger of each experiment must have been investigated pre-
viously by means of animal experimentation; and
3. The experiment must be performed under proper medical protec-
tion and management.
3. Declaration of Helsinki
Another set of widely recognized ethical standards is the "Declara-
tion of Helsinki," 66 which is set forth below:
Recommendations Guiding Doctors in Clinical
Research
INTRODUCTION
It is the mission of the doctor to safeguard the health of the people.
His knowledge and conscience are dedicated to the fulfillment of this
mission.
The Declaration of Geneva of The World Medical Association binds
the doctor with the words: "The health of my patient will be my first
consideration" and the International Code of Medical Ethics which de-
clares that "Any act or advice which could weaken physical or mental
resistance of a human being may be used only in his interest."
Because it is essential that the results of laboratory experiments be
applied to human beings to further scientific knowledge and to help
suffering humanity, The World Medical Association has prepared the
following recommendations as a guide to each doctor in clinical research.
It must be stressed that the standards as drafted are only a guide to
physicians all over the world. Doctors are not relieved from criminal,
civil and ethical responsibilities under the laws of their own countries.
In the field of clinical research a fundamental distinction must be
recognized between clinical research in which the aim is essentially
therapeutic for a patient, and the clinical research, the essential object
of which is purely scientific and without therapeutic value to the person
subjected to the research.
66. This declaration as a project code of ethics on human experimentation drawn
up by the World Medical Association was published in the British Medical Journal,
October 27, 1962. The original project of this was in English. A revised version was
accepted as the final project at the meeting of the World Medical Association in
Helsinki in June, 1964. The original of the project was in French.
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I. BAsic PRINCIPLES
1. Clinical research must conform to the moral and scientific prin-
ciples that justify medical research and should be based on laboratory
and animal experiments or other scientifically established facts.
2. Clinical research should be conducted only by scientifically quali-
fied persons and under the supervision of a qualified medical man.
3. Clinical research cannot legitimately be carried out unless the im-
portance of the objective is in proportion to the inherent risk to the
subject.
4. Every clinical research project should be preceded by careful
assessment of inherent risks in comparison to forseeable benefits to the
subject or to others.
5. Special caution should be exercised by the doctor in performing
clinical research in which the personality of the subject is liable to be
altered by drugs or experimental procedure.
II. CLINICAL RESEARCH COMBINED WITH PROFESSIONAL CARE
1. In the treatment of the sick person, the doctor must be free to use
a new therapeutic measure, if in his judgment it offers hope of saving
life, reestablishing health, or alleviating suffering.
If at all possible, consistent with patient psychology, the doctor should
obtain the patient's freely given consent after the patient has been given
a full explanation. In case of legal incapacity, consent should also be
procured from the legal guardian; in case of physical incapacity the per-
mission of the legal guardian replaces that of the patient.
2. The doctor can combine clinical research with professional care,
the objective being the acquisition of new medical knowledge, only to
the extent that clinical research is justified by its therapeutic value for
the patient.
III. NoN-THERAPEUTIC CLINICAL RESEARCH
1. In the purely scientific application of clinical research carried out
on a human being, it is the duty of the doctor to remain the protector
of the life and health of that person on whom clinical research is being
carried out.
2. The nature, the purpose and the risk of clinical research must be
explained to the subject by the doctor.
3a. Clinical research on a human being cannot be undertaken with-
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out his free consent after he has been informed; if he is legally incom-
petent, the consent of the legal guardian should be procured.
3b. The subject of clinical research should be in such a mental, phys-
ical and legal state as to be able to exercise fully his power of choice.
3c. Consent should, as a rule, be obtained in writing. However, the
responsibility for clinical research always remains with the research
worker; it never falls on the subject even after consent is obtained.
4a. The investigator must respect the right of each individual to safe-
guard his personal integrity, especially if the subject is in a dependent
relationship to the investigator.
4b. At any time during the course of clinical research the subject or
his guardian should be free to withdraw permission for research to be
continued.
The investigator or the investigating team should discontinue the
research if in his or their judgment, it may, if continued, be harmful
to the individual.
The "Declaration of Helsinki" was approved in 1966 by the Amer-
ican Medical Association, the American Federation for Clinical Re-
search, the American Society for Clinical Investigation, the Central
Society for Clinical Research, the American College of Physicians, the
American College of Surgeons, the Society for Pediatric Research, and
the American Academy of Pediatrics, with the following statement:
"We, the undersigned medical organizations, endorse the ethical prin-
ciples set forth in the Declaration of Helsinki by the World Medical
Association concerning human experimentation. These principles sup-
plement the principles of medical ethics to which American physicians
already subscribe."
IV. LAW DIvISION'S GUIDES
The Law Division of the American Medical Association has also is-
sued some guides for physicians in connection with the use of drugs
under clinical investigation. These guides are as follows:
Generally, drugs under clinical investigation should be administered
only where: (1) the informed consent of the patient or his authorized
representative has been obtained; (2) the physician is convinced of the
reasonable accuracy of his diagnosis and, if necessary, has confirmed
it by adequate consultation; and (3) existing methods of treatment
have proven unsatisfactory. The voluntary participation of the patient
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will not excuse a deviation from the physician's obligation to exercise
his best skill in rendering the care required of a reasonable practitioner.
Furthermore, the physician is advised to confine his clinical investiga-
tion of new drugs to those furnished by reputable sources who have
supplied him with comprehensive written information concerning:
(1) animal experimentation; (2) previous clinical investigations, if any;
(3) recommended dosages; (4) contra-indications; (5) possible side-
effects to be watched for, and (6) the safety and possible usefulness
of the drug, from existing data.67
The Law Division has drafted model consent forms for experimental
procedure or treatmentOs and for treatment with drugs under clinical
investigation.6 9 These forms are widely used in the medical profession.
67. AMA LAW DEPARTMENT, MEDICOLEGAL FORMS VITH LEGAL ANALYSIS, 37, footnote
29 (1961).
68. Id. Form 28 reads as follows:
A.M.
Date Time P.M.
I authorize the performance upon
(myself or name
of the following procedure or
of patient)
treatment:
(State nature of procedure or treatment)
The nature and purpose of the procedure or treatment, possible alternative methods
of treatment, the risks involved, and the possibility of complications have been
explained to me. I fully understand that the procedure or treatment to be per-
formed is experimental and unproven by medical experience, and that the conse-
quences are unpredictable.
Signed
(Patient or person authorized to consent for patient)Witness
69. Id. Form 29 reads as follows:
A.M.Date Time P.M.
I authorized Dr. , the
attending physician, to treat (name of patient)
with the drug presently identified as (nameofpatient)
for the following condition:
(Describe symptoms of disease to be treated)
It has been explained to me that the safety and usefulness of the drug in the
treatment of patients for the above condition are now being investigated and
that the manufacturer or distributor has supplied the drug for the purpose of
providing further evidence of its safety and usefulness.
I voluntarily consent to treatment with the drug and release the attending
physician from liability for any results that may occur.
Signed
(Patient or person authorized to consent for patient)Witness.
WILLIAM AND MARY LAW REVIEW
The foregoing ethical standards provide some guidance for the clini-
cal investigators and for the attorneys who are called upon to guide
them. Clearly, these ethical standards are not the last word. Questions
concerning the interpretation or application of the existing standards
will surely arise. Other questions which are not specifically answered
may require the adoption of new ethical guides.
The body authorized to decide questions of medical ethics for phy-
sicians is the Judicial Council of the American Medical Association.
Since the volume of clinical investigation is increasing and since the
ethics of such investigation is being discussed with increasing fre-
quency, the Judicial Council can be expected to issue from time to
time, statements and rulings supplementing and clarifying the standards
established by the Principles of Medical Ethics and the "Helsinki De-
claration."
V. CONCLUSION
At present, the law does not provide detailed specific rules concern-
ing the rights, obligations, and limitations of clinical investigation. It
is doubtful, however, whether it would ever be desirable for these rules
to be established by statute. Statutory rules lack the flexibility that is
necessary for reasonable adaptation to rapidly changing circumstances
such as exist in the field of clinical investigation. The development and
adaptation of rules on a case by case basis would appear to be prefer-
able, even though this process always leaves areas of uncertainty.
At the threshold of this legal process, which is the point at which clin-
ical investigation stands today, many specific legal questions are unde-
cided. But a practical guide for conduct is afforded by the general rules
of law and the ethical standards which have been developed. The con-
scientious clinical investigator can, in these circumstances, carry on
with the kinds of investigation which are essential for the advancement
of medical science and at the same time protect the rights and interests
of his patients and subjects.
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